IN2012DN00640A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00640A
IN2012DN00640A IN640DEN2012A IN2012DN00640A IN 2012DN00640 A IN2012DN00640 A IN 2012DN00640A IN 640DEN2012 A IN640DEN2012 A IN 640DEN2012A IN 2012DN00640 A IN2012DN00640 A IN 2012DN00640A
Authority
IN
India
Prior art keywords
variable domains
hosts
ligands
vectors
compositions
Prior art date
Application number
Inventor
Coulstock Edward
De Angelis Elena
Liu Haiqun
Schon Oliver
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IN2012DN00640A publication Critical patent/IN2012DN00640A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to improved anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variable domains, compositions, nucleic acids, vectors and hosts.
IN640DEN2012 2009-07-16 2010-07-14 IN2012DN00640A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22602809P 2009-07-16 2009-07-16
US30755410P 2010-02-24 2010-02-24
PCT/EP2010/060112 WO2011006915A2 (en) 2009-07-16 2010-07-14 Improved anti-serum albumin binding single variable domains

Publications (1)

Publication Number Publication Date
IN2012DN00640A true IN2012DN00640A (en) 2015-08-21

Family

ID=42829253

Family Applications (1)

Application Number Title Priority Date Filing Date
IN640DEN2012 IN2012DN00640A (en) 2009-07-16 2010-07-14

Country Status (15)

Country Link
US (2) US8679496B2 (en)
EP (1) EP2454285A2 (en)
JP (1) JP2012532620A (en)
KR (1) KR20120038494A (en)
CN (1) CN102574914A (en)
AU (1) AU2010272590B2 (en)
BR (1) BR112012001681A2 (en)
CA (1) CA2768462A1 (en)
EA (1) EA201270174A1 (en)
IL (1) IL217520A0 (en)
IN (1) IN2012DN00640A (en)
MX (1) MX2012000765A (en)
SG (1) SG177601A1 (en)
WO (1) WO2011006915A2 (en)
ZA (1) ZA201200276B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2750477A1 (en) * 2009-02-19 2010-08-26 Stephen Duffield Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
JP2012532620A (en) * 2009-07-16 2012-12-20 グラクソ グループ リミテッド Improved antiserum albumin binding single variable domain
JP2013538566A (en) * 2010-08-13 2013-10-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Improved antiserum albumin binding variants
EP2646467A2 (en) * 2010-12-01 2013-10-09 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
JP6411214B2 (en) 2011-11-11 2018-10-24 ユーシービー バイオファルマ エスピーアールエル Albumin binding antibody and binding fragment thereof
GB201200563D0 (en) * 2012-01-13 2012-02-29 Imp Innovations Ltd Binding molecule
US20190023809A1 (en) * 2015-09-03 2019-01-24 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
NO2768984T3 (en) 2015-11-12 2018-06-09
PL3374392T3 (en) * 2015-11-13 2022-03-28 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
RU2755724C2 (en) 2015-11-18 2021-09-20 Мерк Шарп И Доум Корп. Pd1/ctla4-binding substances
UA121914C2 (en) 2015-11-18 2020-08-10 Мерк Шарп І Доум Корп. Pd1 and/or lag3 binders
US11332519B2 (en) 2015-11-18 2022-05-17 Ablynx N.V. Serum albumin binders
CA3004900C (en) 2015-11-18 2021-08-10 Merck Sharp & Dohme Corp. Ctla4 binders
CN115837014A (en) 2016-05-18 2023-03-24 摩登纳特斯有限公司 Polynucleotide encoding relaxin
WO2018104444A1 (en) 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
SG10202108972RA (en) 2017-01-17 2021-09-29 Ablynx Nv Improved serum albumin binders
ES2994387T3 (en) 2017-01-17 2025-01-23 Ablynx Nv Improved serum albumin binders
PT3583125T (en) 2017-02-16 2025-04-04 Sonnet Biotherapeutics Inc Albumin binding domain fusion proteins
MX2020003562A (en) 2017-10-10 2020-10-01 Numab Therapeutics AG Multispecific antibody.
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
US20220195021A1 (en) * 2019-02-22 2022-06-23 Anwita Biosciences, Inc. Albumin binding antibodies and use thereof
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
WO2021205184A1 (en) 2020-04-09 2021-10-14 Autolus Limited Polypeptide
GB202007441D0 (en) 2020-05-19 2020-07-01 Autolus Ltd Polypeptide
EP3915580A1 (en) 2020-05-29 2021-12-01 Numab Therapeutics AG Multispecific antibody
IT202000013006A1 (en) * 2020-06-01 2021-12-01 Bioreweal S R L PROCESS FOR THE BIOLOGICAL PRODUCTION OF HYDROGEN AND/OR METHANE THROUGH THE ABSORPTION AND BIOLOGICAL CONVERSION OF CARBON DIOXIDE.
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
EP4255926A1 (en) 2020-12-07 2023-10-11 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
WO2022167460A1 (en) 2021-02-02 2022-08-11 Numab Therapeutics AG Multispecific antibodies having specificity for ror1 and cd3
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
CN120712282A (en) 2023-02-17 2025-09-26 阿布林克斯有限公司 Polypeptides that bind neonatal FC receptors
WO2025061919A1 (en) 2023-09-22 2025-03-27 Ablynx Nv Bi- and multivalent albumin binders
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
DE60233509D1 (en) * 2001-06-20 2009-10-08 Fibron Ltd FGFR3 BLOCKING ANTIBODIES, METHOD OF SCREENING THEREOF AND USES THEREOF
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
ATE328906T1 (en) 2002-06-28 2006-06-15 Domantis Ltd DUAL-SPECIFIC LIGANDS WITH INCREASED HALF-LIFE
EP1737962B1 (en) 2004-03-24 2010-09-01 Domantis Limited Gas1 universal leader
KR20070039911A (en) 2004-06-01 2007-04-13 도만티스 리미티드 Bispecific Fusion Antibodies with Enhanced Serum Half-Life
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
JP5185624B2 (en) 2004-12-02 2013-04-17 ドマンティス リミテッド Bispecific antibodies targeting serum albumin and GLP-1 or PYY
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
KR20080077237A (en) * 2005-12-01 2008-08-21 도만티스 리미티드 Competitive domain antibody format that binds interleukin 1 receptor type 1
EA200801170A1 (en) * 2005-12-01 2008-12-30 Домантис Лимитед FORMATS OF NON-COMPETITIVE DOMAIN ANTIBODIES THAT ASSOCIATE WITH INTERLEUKIN RECEPTOR FIRST TYPE 1
EA013878B1 (en) * 2005-12-06 2010-08-30 Домантис Лимитед Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
EP1976991A1 (en) 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
KR20080098382A (en) * 2006-01-24 2008-11-07 도만티스 리미티드 Ligands That Bind IL-4 and / or IL-1
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
WO2009149143A1 (en) * 2008-06-03 2009-12-10 E. I. Du Pont De Nemours And Company Adhesion of polyamides to epoxy resins
US8906035B2 (en) * 2008-06-04 2014-12-09 Ethicon Endo-Surgery, Inc. Endoscopic drop off bag
AU2009256169A1 (en) * 2008-06-06 2009-12-10 Danisco Us Inc. Compositions and methods comprising variant microbial proteases
US10198891B2 (en) * 2008-06-06 2019-02-05 Epona Llc System and method for regulating fuel transactions
JP2012532620A (en) * 2009-07-16 2012-12-20 グラクソ グループ リミテッド Improved antiserum albumin binding single variable domain

Also Published As

Publication number Publication date
AU2010272590B2 (en) 2013-10-10
CN102574914A (en) 2012-07-11
WO2011006915A2 (en) 2011-01-20
EP2454285A2 (en) 2012-05-23
US8679496B2 (en) 2014-03-25
MX2012000765A (en) 2012-02-13
BR112012001681A2 (en) 2019-09-24
SG177601A1 (en) 2012-02-28
JP2012532620A (en) 2012-12-20
AU2010272590A1 (en) 2012-02-02
US20120114647A1 (en) 2012-05-10
IL217520A0 (en) 2012-02-29
CA2768462A1 (en) 2011-01-20
WO2011006915A3 (en) 2011-03-03
US20140140996A1 (en) 2014-05-22
KR20120038494A (en) 2012-04-23
ZA201200276B (en) 2012-09-26
EA201270174A1 (en) 2012-07-30

Similar Documents

Publication Publication Date Title
IN2012DN00640A (en)
MX2011008752A (en) Improved anti-serum albumin binding variants.
MX2012013406A (en) Improved anti-serum albumin binding variants.
MX2011008749A (en) Improved anti-serum albumin binding variants.
WO2012072731A3 (en) Improved anti-serum albumin binding single variable domains
CY1119567T1 (en) Therapeutic Peptides
WO2014083208A9 (en) Binding proteins comprising at least two repeat domains against her2
HK1219983A1 (en) Therapeutic peptides
MX2012003939A (en) Drug fusions and conjugates with extended half life.
WO2013072813A3 (en) Cytotoxic peptides and antibody drug conjugates thereof
UA106900C2 (en) LibreOfficeDR5-BINDING POLYPEPTIDE
WO2011086143A3 (en) Liver targeting domain antibodies
MX2013002055A (en) Improved anti-serum albumin binding variants.
WO2011112566A3 (en) Basigin binding proteins
WO2018062402A8 (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
WO2014044793A3 (en) Cd22-binding peptides
MX2015014198A (en) Antibodies targeting m-csf.
WO2016005474A8 (en) Site selective conjugation of an oligonucleotide conjugate or a small molecule to a metal binding protein
WO2012136792A3 (en) Cck compositions
CR20110473A (en) VARIATIONS OF UNION TO ANTI-ALBÚMINA DE SERERO IMPROVED.
HK1196856A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
HK1171028A (en) Il-17 binding compounds and medical uses thereof
TH148778A (en) Therapeutic peptides